These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28295491)

  • 1. National trends in the treatment of diabetic nephropathy in the United States.
    Ajiboye O; Segal JB
    J Clin Pharm Ther; 2017 Jun; 42(3):311-317. PubMed ID: 28295491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
    Clemens KK; Liu K; Shariff S; Schernthaner G; Tangri N; Garg AX
    Diabetes Obes Metab; 2016 Jun; 18(6):607-14. PubMed ID: 26939711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States.
    Stafford RS; Monti V; Furberg CD; Ma J
    Hypertension; 2006 Aug; 48(2):213-8. PubMed ID: 16785334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unmet need in diabetic nephropathy: failed drugs or trials?
    de Zeeuw D; Heerspink HJL
    Lancet Diabetes Endocrinol; 2016 Aug; 4(8):638-640. PubMed ID: 27160545
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy.
    Qiu DD; Liu J; Shi JS; An Y; Ge YC; Zhou ML; Jiang S
    Chin Med J (Engl); 2018 Nov; 131(22):2658-2665. PubMed ID: 30425192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors.
    Mahmoudpour SH; Asselbergs FW; de Keyser CE; Souverein PC; Hofman A; Stricker BH; de Boer A; Maitland-van der Zee AH
    Int J Clin Pharm; 2015 Dec; 37(6):1095-103. PubMed ID: 26159317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the influence of physicians on the underuse of drugs in diabetic nephropathy in Taiwan.
    Huang LY; Yeh HL; Su S; Wang TC; Hsieh JY
    J Nephrol; 2013; 26(1):16-24. PubMed ID: 22641577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the United States: a cross-sectional analysis of the national health and nutrition examination survey.
    Sonawane KB; Qian J; Hansen RA
    Clin Ther; 2015 Jan; 37(1):188-96. PubMed ID: 25524390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective.
    Song ZH; Wang XL; Wang XF; Liu J; Luo SQ; Xu SS; Cheng X; Bai J; Dong LM; Zhang C; Zhou JB
    Front Endocrinol (Lausanne); 2022; 13():900114. PubMed ID: 35707460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study.
    Hirt MN; Muttardi A; Helms TM; van den Bussche H; Eschenhagen T
    Clin Res Cardiol; 2016 May; 105(5):441-50. PubMed ID: 26552905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of the utilization of angiotensin receptor blockers in hypertension].
    Peña Cabia S; Ricote Lobera I; Santos Mena B; Hidalgo Correas FJ; Climent Florez B; García Díaz B
    Farm Hosp; 2013; 37(5):394-8. PubMed ID: 24128102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004.
    Ma J; Lee KV; Stafford RS
    Hypertension; 2006 Nov; 48(5):846-52. PubMed ID: 16982967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with SGLT2 inhibitors for diabetic kidney disease.
    Cai Y; Liu X; Xu G
    Biomed Pharmacother; 2020 Jul; 127():110192. PubMed ID: 32559844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan.
    Yeh HL; Huang LY; Su S; Yang MC; Wang TC
    Health Policy; 2011 May; 100(2-3):196-202. PubMed ID: 21146895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.